Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Overview
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Companies Involved in Therapeutics Development
Arvis Inc
Biogenera SpA
Escend Pharmaceuticals Inc
Gibson Oncology LLC
Kintor Pharmaceutical Ltd
Kronos Bio Inc
MecRx Pty Ltd
OncoViRx LLC
Peptomyc SL
PYCTX Ltd
SyntheX Inc
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Drug Profiles
Amy-22 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGA-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit MYC for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ES-4000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-19077 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-1701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMO-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Myc for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target c-Myc for Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit c-Myc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit cMyc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MYC and NFKB for Lymphomas and Leukemias - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MYC and TOP1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MYC for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STX-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit C-Myc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Dormant Products
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Discontinued Products
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Product Development Milestones
Featured News & Press Releases
Jul 30, 2020: VHIO and home-grown spin-off Peptomyc S.L receive further funding to bring Omomyc closer to the clinic
Jun 22, 2020: Pioneer Pharmaceuticals released the latest research results of c-Myc inhibitors at the AACR annual meeting
Apr 01, 2019: First published demonstration of the success of Myc inhibition by Omomyc mini-protein hits Science Translatiol Medicine and the news
Mar 26, 2019: Preclinical validation of new cancer inhibitor from EIT Health-supported Peptomyc
Mar 14, 2019: A new approach to drugging a difficult cancer target
Dec 09, 2015: Combition therapy escalates potency of Phylogica peptides against MYC-driven cancer
Nov 16, 2015: Phylogica exceeds gold - standard for treatment of MYC - driven cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Arvinas Inc, H2 2020
Pipeline by Biogenera SpA, H2 2020
Pipeline by Escend Pharmaceuticals Inc, H2 2020
Pipeline by Gibson Oncology LLC, H2 2020
Pipeline by Kintor Pharmaceutical Ltd, H2 2020
Pipeline by Kronos Bio Inc, H2 2020
Pipeline by MecRx Pty Ltd, H2 2020
Pipeline by OncoViRx LLC, H2 2020
Pipeline by Peptomyc SL, H2 2020
Pipeline by PYCTX Ltd, H2 2020
Pipeline by SyntheX Inc, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020